The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-κB)

This publication has 53 references indexed in Scilit:

• Anandamide Inhibits Nuclear Factor-κB Activation through a Cannabinoid Receptor-Independent Pathway
  Molecular Pharmacology, 2003
• Recombinant adenoviral expression of dominant negative IκBα protects brain from cerebral ischemic injury
  Biochemical and Biophysical Research Communications, 2002
• Transcription Factor NF-κB Is Necessary for Up-regulation of Type 1 Angiotensin II Receptor mRNA in Rat Cardiac Fibroblasts Treated with Tumor Necrosis Factor-α or Interleukin-1β
  Published by Elsevier ,2002
• Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
  The FASEB Journal, 2000
• The Distinct Roles of TRAF2 and RIP in IKK Activation by TNF-R1
  Immunity, 2000
• Chronic ▵⁹‐Tetrahydrocannabinol Treatment Produces a Time‐Dependent Loss of Cannabinoid Receptors and Cannabinoid Receptor‐Activated G Proteins in Rat Brain
  Journal of Neurochemistry, 1999
• Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation
  Science, 1996
• THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
  Annual Review of Immunology, 1996
• HU-211, a Novel Noncompetitive N -Methyl- d- Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat
  Stroke, 1995
• Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
  Cell, 1987